Latest news with #Veris
Yahoo
02-07-2025
- Business
- Yahoo
Therma-Tru Introduces Veris Modern Grain Entryways
Sleek glass, aluminum and wood-grained fiberglass panels provide an elevated, mixed-material aesthetic MAUMEE, Ohio, July 02, 2025--(BUSINESS WIRE)--Therma-Tru has launched the striking new Veris Modern Grain entryway system, combining refined design with enduring performance for any home. The only large aluminum door in the market featuring Therma-Tru Walnut-grained fiberglass panels and sleek glass, Modern Grain systems deliver the beauty of real wood with superior durability. "Our stunning new Modern Grain doors give architects and designers the flexibility to create serious curb appeal — with options like privacy or clear glass, six rich wood finishes and a versatile grid system," said Eric Dotson, vice president of product management B2B for Therma-Tru. "They're also built on our legacy of innovation and performance." As with all Veris doors, Modern Grain entryway systems feature an aluminum frame that resists warping and deterioration and is backed by a lifetime warranty and a 10-year finish warranty. Each door system offers bespoke selections in operation, configuration, stain and glass—choose the size needed, the desired look, and the level of privacy preferred. This blend of industrial strength and warm, natural finishes delivers a modern feel that also complements transitional home styles. Fiberglass insert options let homeowners, architects and designers balance natural light and privacy along with their design preferences. Glass Options For varying levels of light and visibility, glass options include Low-E Clear, and a new Satin privacy glass that provides a subtle, smooth, seamless finish for an understated elegance. Handcrafted Look Therma-Tru Classic Craft Walnut-grain fiberglass panels feature revolutionary AccuGrain technology, for a look and feel that is virtually indistinguishable from real wood. Color Variations A curated selection of six PrismaGuard premium stain options provides rich tones that add dimension. Available Sizes Heights: 6'8", 7'0", 8'0", 9'0", 10'0" Widths (Hinged): 3'0", 3'6", 4'0"; (Pivot): 3'6", 4'0", 5'0", 6'0" Configurations Available in pivot or hinged configurations, offering flexibility for various architectural styles and functional needs. Veris door systems blend high-end style with unique functionality to create elegant openings in pivot, hinged, folding, and sliding configurations. Crafted from premium aluminum, stainless steel, and polymer components with advanced thermal technology, Veris doors offer eco-friendly, virtually maintenance-free living and long-lasting performance. Each comes backed by a one-time transferable lifetime limited warranty and a balance-transferable 10-year limited warranty on finish. For more information, visit About Therma-Tru Therma-Tru is the leading entry door brand most preferred by building professionals. Founded in 1962, Therma-Tru pioneered the fiberglass entry door industry, and today offers a complete portfolio of entry door system solutions proven to outlast and outperform wood and steel. Therma-Tru is part of Fortune Brands Innovations, Inc.(NYSE: FBIN). Learn more at About Fortune Brands Innovations Fortune Brands Innovations, Inc. (NYSE: FBIN), headquartered in Deerfield, Ill., is a brand, innovation and channel leader focused on exciting, supercharged categories in the home products, security and commercial building markets. The Company's growing portfolio of brands includes Moen, House of Rohl, Aqualisa, Emtek, Therma-Tru, Larson, Fiberon, Master Lock, SentrySafe, Yale residential and August. To learn more about FBIN, its brands and environmental, social and governance (ESG) commitments, visit View source version on Contacts Amy Evans317-873-8100 x281amy@ Sign in to access your portfolio
Business Wire
02-07-2025
- Business
- Business Wire
Therma-Tru Introduces Veris Modern Grain Entryways
MAUMEE, Ohio--(BUSINESS WIRE)--Therma-Tru has launched the striking new Veris Modern Grain entryway system, combining refined design with enduring performance for any home. The only large aluminum door in the market featuring Therma-Tru Walnut-grained fiberglass panels and sleek glass, Modern Grain systems deliver the beauty of real wood with superior durability. The only large aluminum door in the market featuring Therma-Tru Walnut-grained fiberglass panels and sleek glass, Modern Grain systems deliver the beauty of real wood with superior durability. Share 'Our stunning new Modern Grain doors give architects and designers the flexibility to create serious curb appeal — with options like privacy or clear glass, six rich wood finishes and a versatile grid system,' said Eric Dotson, vice president of product management B2B for Therma-Tru. 'They're also built on our legacy of innovation and performance.' As with all Veris doors, Modern Grain entryway systems feature an aluminum frame that resists warping and deterioration and is backed by a lifetime warranty and a 10-year finish warranty. Each door system offers bespoke selections in operation, configuration, stain and glass—choose the size needed, the desired look, and the level of privacy preferred. This blend of industrial strength and warm, natural finishes delivers a modern feel that also complements transitional home styles. Fiberglass insert options let homeowners, architects and designers balance natural light and privacy along with their design preferences. Glass Options For varying levels of light and visibility, glass options include Low-E Clear, and a new Satin privacy glass that provides a subtle, smooth, seamless finish for an understated elegance. Handcrafted Look Therma-Tru Classic Craft Walnut-grain fiberglass panels feature revolutionary AccuGrain technology, for a look and feel that is virtually indistinguishable from real wood. Color Variations A curated selection of six PrismaGuard premium stain options provides rich tones that add dimension. Available Sizes Heights: 6'8", 7'0", 8'0", 9'0", 10'0" Widths (Hinged): 3'0", 3'6", 4'0"; (Pivot): 3'6", 4'0", 5'0", 6'0" Configurations Available in pivot or hinged configurations, offering flexibility for various architectural styles and functional needs. Veris door systems blend high-end style with unique functionality to create elegant openings in pivot, hinged, folding, and sliding configurations. Crafted from premium aluminum, stainless steel, and polymer components with advanced thermal technology, Veris doors offer eco-friendly, virtually maintenance-free living and long-lasting performance. Each comes backed by a one-time transferable lifetime limited warranty and a balance-transferable 10-year limited warranty on finish. For more information, visit About Therma-Tru Therma-Tru is the leading entry door brand most preferred by building professionals. Founded in 1962, Therma-Tru pioneered the fiberglass entry door industry, and today offers a complete portfolio of entry door system solutions proven to outlast and outperform wood and steel. Therma-Tru is part of Fortune Brands Innovations, Inc. (NYSE: FBIN). Learn more at About Fortune Brands Innovations Fortune Brands Innovations, Inc. (NYSE: FBIN), headquartered in Deerfield, Ill., is a brand, innovation and channel leader focused on exciting, supercharged categories in the home products, security and commercial building markets. The Company's growing portfolio of brands includes Moen, House of Rohl, Aqualisa, Emtek, Therma-Tru, Larson, Fiberon, Master Lock, SentrySafe, Yale residential and August. To learn more about FBIN, its brands and environmental, social and governance (ESG) commitments, visit
Yahoo
03-06-2025
- Business
- Yahoo
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center. This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Veris Cancer Care Platform™. Pursuant to the agreement Veris and OSUCCC – James entered into a long-term, multi-project strategic partnership to utilize, and further the development and commercialization of the Veris Cancer Care Platform and its implantable physiologic monitor. The agreement includes expansion of commercial utilization of the platform across cancer care service lines; full electronic health record (EHR) integration; initiation of a large clinical registry of patients enrolled on the platform to be launched in the coming weeks; and launch of a large clinical trial of patients receiving the implantable physiologic monitor, to be launched upon FDA clearance, expected next year. It also calls for close collaboration on the development of clinical cancer care pathways, platform software enhancements, and best practices for clinical use of the implantable physiological monitor. "We are thrilled to advance our strategic partnership with OSUCCC – James, one of the largest and most prestigious academic cancer centers in the nation, following the successful completion of a pilot program demonstrating the strong clinical utility of our platform," said Brian deGuzman, M.D., Chief Operating Officer of Veris Health. "This commercial transition represents a major milestone for Veris. We look forward to working closely with the OSUCCC – James team to enhance the care of thousands of cancer patients there every year." "At the OSUCCC – James, delivering personalized, world-class cancer care remains our top priority," said David Cohn, M.D., M.B.A., Chief Operating Officer and Chair of Gynecologic Oncology at The James Cancer Hospital and Solove Research Institute. "After a successful pilot program, we are excited to be entering into a long-term strategic partnership with Veris Health to expand access to the Veris Cancer Care Platform and enhance the care of our patients." The Veris Cancer Care Platform is a comprehensive digital cancer care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction. Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted alongside a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance. Cancer centers and oncology practices interested in learning more about Veris and the Veris Platform, please visit to contact a company representative. About PAVmed and Veris PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Veris Health Inc., is a digital health company whose lead product is a digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris cancer care platform. Its other majority-owned subsidiary, Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. For more and for more information about PAVmed, please visit For more information about Veris Health, please visit For more information about Lucid Diagnostics, please visit About The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (the "OSUCCC – James"), is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic health center and a freestanding cancer hospital on the campus of one of the nation's largest public universities. The OSUCCC – James has been designated as an NCI Comprehensive Cancer Center since 1976. Also, it is one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer agents provided by the NCI. As the cancer program's adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet® recognition, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation. The OSUCCC – James is a global leader in such emerging disciplines as cellular therapy and immuno-oncology. In 2017, the OSUCCC – James was among the first hospitals in the United States to offer the first cellular therapy for blood cancers, known as CAR T-cell therapy, and is playing a major role in the continuing development of this and other cellular therapies. To learn more about cancer treatment and clinical trials at the OSUCCC – James, visit Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia: SOURCE PAVmed Inc. Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification
Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. PAVmed Inc (NASDAQ:PAVM) has successfully stabilized its corporate structure and balance sheet, positioning itself as a diversified commercial life science company. The company reported a significant strengthening of its balance sheet with a public offering netting $16.1 million, extending its financial runway well into 2026. Lucid, a subsidiary of PAVmed Inc (NASDAQ:PAVM), is on the cusp of key milestones, including Medicare coverage, and reported revenue of $800,000 with test volumes at the upper end of their target range. PAVmed Inc (NASDAQ:PAVM) has secured financing to restart development of a critical implantable monitor for its subsidiary, Veris, and is close to finalizing a strategic partnership. The company is actively pursuing expansion into the biopharma space, leveraging its infrastructure and track record to explore attractive assets and partnerships. PAVmed Inc (NASDAQ:PAVM) faces uncertainties related to forward-looking statements, which are subject to risks that could cause actual results to differ materially. The company is still awaiting a response from the Medicare program regarding coverage for its e-cigarette diagnostic, which is crucial for accelerating commercialization. There are significant differences in financial reporting due to the deconsolidation of Lucid, which may blur historical understanding of PAVmed Inc (NASDAQ:PAVM)'s financials. The company has a complex corporate structure with multiple subsidiaries, which may pose challenges in management and strategic alignment. PAVmed Inc (NASDAQ:PAVM) is pursuing multiple initiatives simultaneously, including expansion into biopharma, which could stretch its resources and focus. Warning! GuruFocus has detected 8 Warning Signs with PAVM. Q: Now that the pilot program is complete, can you share any feedback from physicians and patients, and has this influenced any changes to the platform before commercialization? A: We've received excellent feedback, meeting all pre-specified performance metrics, including patient satisfaction and clinical success. There is significant enthusiasm, especially with the upcoming implantable monitor. No immediate changes to the platform are needed, but we've learned valuable lessons on implementation processes, which we are applying moving forward. (Respondent: Unidentified_6) Q: Does OSU have exclusive rights to the Veris platform, or are you in talks with other centers? A: OSU has some local rights but nothing that limits our broader commercialization efforts. We aim to use our strong relationship with OSU as a model to replicate at other cancer centers nationwide. (Respondent: Unidentified_6) Q: Can you elaborate on your expansion into the biopharma segment and the financing strategy for this venture? A: Our corporate structure and balance sheet adjustments have positioned us to explore new opportunities, including biopharma. We plan to leverage our infrastructure and track record to pursue attractive assets, particularly those struggling to raise private capital. Financing will follow our model of independently financed subsidiaries, similar to Lucid and Veris. (Respondent: Unidentified_6) Q: Has market volatility affected your ability to raise capital? A: No, we've been fortunate to attract investors aligned with our vision. Our recent financing activities demonstrate our ability to secure necessary funds, and we expect to continue accessing both private and public capital as needed. (Respondent: Unidentified_4) Q: What is the strategic rationale for expanding into biopharma now, given your existing commitments? A: Our structure allows us to pursue shareholder value across various sectors. The biopharma expansion is driven by opportunities identified with our board member, Dr. Sande Agarwal, and aligns with our history of leveraging infrastructure for new ventures. We believe this sector offers streamlined pathways to value creation. (Respondent: Unidentified_6) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-04-2025
- Business
- Yahoo
Veris Is Buying the Whole Tower--And Betting Big on Jersey City's Luxury Boom
Veris Residential (NYSE:VRE) is closing in on full ownership of one of Jersey City's crown jewelsan upscale waterfront apartment tower at 200 Greene Street. The company is set to buy out the remaining minority stake in the Jersey City Urby building in a deal valuing the property at around $430 million, according to a source familiar with the matter. Veris already owns 85% of the asset and is now taking steps to consolidate its position in one of the most sought-after rental markets in the country. Warning! GuruFocus has detected 5 Warning Signs with VRE. This isn't just about a bigger piece of the pieit's about controlling the whole bakery. The Urby tower isn't your average multifamily play. It's a short walk from the PATH train into NYC, boasts a yoga studio, pool, dog park, EV chargers, and a cafe in the lobby. Rents here aren't cheap eitheraveraging $2,200 for a two-bedroom, roughly 10% higher than the national average. In short, it's prime real estate, purpose-built for urban professionals who value both lifestyle and location. Newmark brokers Adam Spies and Adam Doneger advised on the transaction, which now gives Veris a runway to capture 100% of the income, upside, and strategic control. As Jersey City's luxury housing market continues to outpace expectations, Veris is positioning itself at the center of that growth. This deal isn't just another real estate buyoutit's a calculated move to double down on cash-flowing core assets in a high-demand corridor, with long-term returns firmly in sight. This article first appeared on GuruFocus. Sign in to access your portfolio
